Dyspepsia commonly known as indigestion a gastrointestinal disorder affecting millions globally. It is a condition that causes discomfort, pain, and a feeling of fullness or bloating in the upper abdomen. Dyspepsia can be caused by various factors such as eating too quickly, consuming spicy or fatty foods, or as a side effect of medication.
Access full Report @ https://www.databridgemarketresearch.com/reports/global-dyspepsia-drug-market
The increasing prevalence of dyspepsia is one of the key driving factors for the growth of the dyspepsia drug market. The rising incidence of dyspepsia can be attributed to several factors, such as changes in lifestyle, dietary habits, and the aging population. As people age, they are more susceptible to digestive problems, including dyspepsia. With the growing number of older adults, there is a higher demand for dyspepsia drugs.
In addition, different digestive diseases like irritable bowel syndrome, gastroparesis, gastritis, and peptic ulcer disease also cause dyspepsia. The increasing prevalence of the mentioned disease leads to an increase in the incidence and prevalence of dyspepsia among the population
Data Bridge Market Research analyses that the Dyspepsia Drug Market is expected to grow at a CAGR of 5.2% in the forecast period of 2023 to 2030 and is expected to reach USD 1,137,503.43 thousand by 2030. The increase in the prevalence of dyspepsia and the rising adoption of unhealthy lifestyles is projected to propel the growth of the market as they create new opportunities for dyspepsia conditions.
Key Findings of the Study
The rise in the adoption of unhealthy lifestyles globally is expected to drive the market's growth rate
In recent years, there has been a rise in the adoption of unhealthy lifestyles, which has contributed to an increase in the prevalence of dyspepsia. Unhealthy lifestyle choices such as a diet high in processed foods, lack of exercise, and excessive alcohol consumption can all contribute to dyspepsia.
As a result, there has been a corresponding increase in the demand for dyspepsia drugs as people seek relief from their symptoms. The dyspepsia drug market has responded to this demand with a variety of medications, including proton pump inhibitors, H2 receptor antagonists, and antacids.
The rise in the adoption of unhealthy lifestyles can be attributed to several factors, including changes in dietary habits, increasing stress levels, and a sedentary lifestyle. Modern life is often characterized by long working hours, high levels of stress, and easy access to fast food and other unhealthy options. These factors can contribute to dyspepsia and other related conditions, such as gastroesophageal reflux disease (GERD).
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in Thousand, Volumes in Units, and Pricing in USD
|
|
Segments Covered
|
Type (Organic Dyspepsia, Non-Ulcer Dyspepsia, Drug Induced Dyspepsia, and Others), Treatment Type (Medication and Surgery), Drug Type (Branded and Generic), Prescription (Without Prescription Drugs and Prescription Drugs), Route of Administration (Oral and Injectable), Gender (Male and Female), End User (Hospitals, Clinics, Homecare settings, Specialty Clinics, Ambulatory Surgical Centers, Academic and Government Research Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales)
|
|
Countries Covered
|
U.S., Canada, and Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Denmark, Sweden, Poland, Norway, Finland, and Rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, New Zealand, Vietnam, Taiwan, and Rest of Asia-Pacific, Brazil, Argentina, and Rest of South America, South Africa, Egypt, Bahrain, United Arab Emirates, Kuwait, Oman, Saudi Arabia, Qatar, and Rest of Middle East and Africa
|
|
Market Players Covered
|
Bayer AG (Germany), Mankind Pharma (India), Cadila Pharmaceuticals. (India), Salix Pharmaceuticals, and its affiliates (U.S.), Sanofi (France), Aosaikand Pharmaceutical Co., Ltd. (China), Hanmi Pharm. Co., Ltd. (Korea), ANI Pharmaceuticals, Inc (U.S.), Asterisk Laboratories (I) Pvt. Ltd (India), Lupin (India), AstraZeneca (U.K.), RedHill Biopharma Ltd. (Israel), Abbott (U.S.), McNeil Consumer Pharmaceuticals Co. (U.S.), Otsuka Pharmaceutical Co., Ltd.(Japan), Takeda Pharmaceutical Company Limited. (Japan), ZERIA Pharmaceutical Co., Ltd (Japan), Procter & Gamble (U.S.), Perrigo Company plc (Ireland), Reckitt Benckiser (England), WOODWARD PHARMA (U.S.) and Prestige Consumer Healthcare Inc. (U.S.), among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The global dyspepsia drug market is segmented into type, treatment type, drug type, prescription, route of administration, gender, end user, and distribution channel.
- On the basis of type, the global dyspepsia drug market is segmented into organic dyspepsia, non-ulcer dyspepsia, drug induced dyspepsia, and others. In 2023, the non-ulcer dyspepsia segment is expected to dominate the global dyspepsia drug market with 76.64% market share due to the increasing prevalence of dyspepsia among the population.
- On the basis of treatment type, the global dyspepsia drug market is segmented into segmented into medication and surgery. In 2023, the medication segment is expected to dominate the dyspepsia drug market with 90.48% market share.
- On the basis of drug type, the global dyspepsia drug market is segmented into generic and branded. In 2023, the generic segment is expected to dominate the dyspepsia drug market with 77.17% market share.
In 2023, the generic segment of the drug type segment is anticipated to dominate the dyspepsia drug market
- On the basis of the prescription, the global dyspepsia drug market is segmented into without prescription drugs and prescription drugs. In 2023, the without prescription drugs segment is expected to dominate the dyspepsia drug market with 53.99% market share.
- On the basis of the route of administration, the global dyspepsia drug market is segmented into oral and injectable. In 2023, the oral segment is expected to dominate the dyspepsia drug market with 89.88% market share.
- On the basis of gender, the global dyspepsia drug market is segmented into male and female. In 2023, the female segment is expected to dominate the dyspepsia drug market with 59.57% market share.
- On the basis of end user, the global dyspepsia drug market is segmented into hospitals, clinics, homecare settings, specialty clinics, ambulatory surgical centers, academic and government research institutes, and others. In 2023, the hospitals segment is expected to dominate the dyspepsia drug market with 34.08% market share.
In 2023, the hospitals segment is expected to hold the largest share of end user segment in the dyspepsia drug market as a higher number of patients prefer to visit hospitals for different dyspepsia problems
- Based on the distribution channel, the global dyspepsia drug market is segmented into direct tenders and retail sales. In 2023, the retail sales segment is expected to dominate the dyspepsia drug market with 75.01% market share as most of the products related to dyspepsia drug are directly distributed to various places such as hospitals, clinics, homecare settings, specialty clinics, ambulatory surgical centers, academic and government research institutes, and others.
Major Players
Data Bridge Market Research recognizes the following companies as the major dyspepsia drug market players in dyspepsia drug market are Bayer AG (Germany), Mankind Pharma (India), Cadila Pharmaceuticals. (India), Salix Pharmaceuticals, and its affiliates (U.S.), Sanofi (France), Aosaikand Pharmaceutical Co., Ltd. (China), Hanmi Pharm. Co., Ltd. (Korea), ANI Pharmaceuticals, Inc (U.S.), Asterisk Laboratories (I) Pvt. Ltd (India), Lupin (India), AstraZeneca (U.K.), RedHill Biopharma Ltd. (Israel), Abbott (U.S.), McNeil Consumer Pharmaceuticals Co. (U.S.), Otsuka Pharmaceutical Co., Ltd.(Japan), Takeda Pharmaceutical Company Limited. (Japan), ZERIA Pharmaceutical Co., Ltd (Japan), Procter & Gamble (U.S.), Perrigo Company plc (Ireland), Reckitt Benckiser (England), WOODWARD PHARMA (U.S.) and Prestige Consumer Healthcare Inc. (U.S.), among others.
Market Developments
- In April 2023, Lupin announced that it had launched a regional reference laboratory in Bengaluru. Thus, strengthening its presence in South India.
- In November 2022, Abbott announced that it had been awarded by the Consumer Technology Association (CTA) with three CES 2023 Innovation Awards for its life-changing technologies that are advancing the health tech industry and improving the lives of people worldwide.
- In July 2022, ANI Pharmaceuticals, Inc. announced the purchase of four abbreviated new drug applications (ANDAs) from Oakrum Pharma, LLC, and a privately owned biopharmaceutical company. This helps the organization in developing more revenue.
- In March 2022, AstraZeneca partnered with The National Fish and Wildlife Foundation (NFWF) to plant and sustain one million trees in the United States by the end of 2025. This initiative is part of the Company's flagship Ambition Zero Carbon program to decarbonize its global operations by eliminating, reducing, and substituting for our greenhouse gas emissions and becoming carbon negative across our value chain by 2030, in line with science-based targets. This helps the organization in developing its image in terms of the green world.
- In September 2020, Cadila Pharmaceuticals announced the launch of Obetocad in India, a generic version of Ocaliva (Obeticholic Acid) primarily used for the treatment of Primary Biliary Cholangitis. This product launch has helped the company in product portfolio expansion.
Regional Analysis
Geographically, the countries covered in the global dyspepsia drug market report are U.S., Canada, and Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Denmark, Sweden, Poland, Norway, Finland, and Rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, New Zealand, Vietnam, Taiwan, and Rest of Asia-Pacific, Brazil, Argentina, and Rest of South America, South Africa, Egypt, Bahrain, United Arab Emirates, Kuwait, Oman, Saudi Arabia, Qatar, and Rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is the dominant region in the dyspepsia drug market during the forecast period 2023 - 2028
In 2023, North America dominated the dyspepsia drug market owing to the higher level of investments by U.S. manufacturers and the increasing prevalence of dyspepsia in the U.S. North America will continue to dominate the dyspepsia drug market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing adoption of advanced unhealthy lifestyle. Additionally, the increasing number of cases of dyspepsia and the rising geriatric population is expected to further enhance the market's growth rate in this region.
Asia-Pacific is estimated to be the fastest growing region in the dyspepsia drug market in the forecast period 2023 - 2030
Asia-Pacific is expected to grow during the forecast period due to the presence of major market players and the rapid development of medical facilities in emerging economies in this region. In addition to this, the rising level of healthcare expenditure for urinary disorders and increasing per-capita income is expected to propel the market's growth rate in this region.
For more detailed information about the dyspepsia drug market report, click here – https://www.databridgemarketresearch.com/reports/global-dyspepsia-drug-market
